Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal ...
Allschwil, Switzerland - February 06, 2026Idorsia Ltd (SIX: IDIA) announces the design of its FDA-agreed Phase 3 registration program for lucerastat in Fabry disease. Building on the robust biomarker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results